Ryboquin Overview

  • Founded
  • 2013
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Ryboquin General Information

Description

Developer of gene therapy designed to treat cancer patients. The company's gene therapy uses nano-technology, commercializes human cancer medicines and tumor apoptosis enhancer drugs to optimize chemotherapy, enabling patients to receive effective oncology therapies at an affordable cost.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • Ettrick Riverside, Dunsdale Road
  • Scottish Borders
  • Selkirk TD7 5EB
  • Scotland, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ryboquin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Aug-2018 00.000 Completed Out of Business
2. Early Stage VC 27-Jul-2017 00.000 00.000 00.000 Completed Startup
1. Early Stage VC 07-Jan-2016 $2.19M $2.19M 00.000 Completed Startup
To view Ryboquin’s complete valuation and funding history, request access »

Ryboquin Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 1 00,000,000 00.000000 00.00 00.00 00 00.00 00.00
Ordinary 000,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Ryboquin’s complete cap table history, request access »

Ryboquin Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 19-Jul-2018 000000000000000000 00.000 Other Healthcare Technology Systems 0000 000000
To view Ryboquin’s complete acquisitions history, request access »